Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFXL-assisted Picato for basal cell carcinoma
2017-002843-14Phase 2Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Jul 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ingenol mebutate in basal cell carcinoma (BCC), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoints: Local skin reactions and Safety. Started Jul 2017; status: completed.
02
Drugs
ingenol mebutate
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2017-002843-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002843-14.